Drugs / Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
also known as
Anti-MIF Antibody
Protein / enzyme biologic targets MIF via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01541670 | Nov 2011 → Dec 2012 | systemic lupus erythematosus | Baxalta now part of Shire | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01541670 ↗ |
| Known as | Anti-MIF Antibody | “The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.” NCT01541670 ↗ |
| Action | Inhibit | “Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody” NCT01541670 ↗ |
| Modality | Protein / enzyme biologic | “Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody” NCT01541670 ↗ |
| Route | Intravenous | “Intravenous injection” NCT01541670 ↗ |
| Target | MIF | “Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody” NCT01541670 ↗ |